Adding immunity to human kidney-on-a-chip adv

T cell bispecific antibodies (TCBs) are an emerging class of immunotherapeutics with several TCBs approved by the FDA for the treatment of leukemias, lymphomas, and myelomas. TCBs label tumor cells with one of their ends, and attract immune cells with another end to coerce them into tumor cell killing. However, one major challenge in the development of TCBs are “on-target, off-tumor” toxicities at sites in the body that also express TCB-targeted antigens. A new collaboration of Jennifer Lewis’ group and researchers from the Roche Innovation Centers in Switzerland and Germany now created an immune-infiltrated human kidney organoid-on-chip model that allows kidney toxicity of TCBs.

Related Keywords

Boston ,Massachusetts ,United States ,Spaulding Rehabilitation Hospital ,Tufts University ,Switzerland ,Massachusetts Institute Of Technology ,Germany ,Munich ,Bayern ,University Of Massachusetts Medical School ,Boston University ,Berlin ,Benjamin Boettner ,Antje Christine Walz ,Mariana Mata ,Ken Hiratsuka ,Jennifer Lewis ,Katharina Kroll ,Donald Ingber ,Virginie Micallef ,Kimberly Homan ,Joseph Bonventre ,Marcel Gruber ,Jennifer Lewi ,Annie Moisan ,Ryuji Morizane ,Alejandro Carpy ,Method Of Research ,Harvard Medical School ,Beth Israel Deaconess Medical Center ,Proceedings Of The National Academy Sciences ,Roche Innovation Center Basel ,National Center ,Arts Sciences ,Roche Innovation Centers In Basel ,International Foundation Of Ethical Research ,Harvard Johna Paulson School Of Engineering ,D Organ Engineering Initiative ,Drug Administration ,Wyss Institute ,Farber Cancer Institute ,Roche Innovation Center ,Roche Pharma Research Early Development ,Genentech ,Biologically Inspired Engineering ,Harvard University ,Harvard John ,Applied Sciences ,Roche Innovation ,Wilm Tumor ,Wyss Core Faculty ,Wyss Professor ,Morgan Engineering ,Postdoctoral Fellow ,Wyss Founding Director ,Judah Folkman Professor ,Vascular Biology ,Boston Children ,Bioinspired Engineering ,Estelle Marrer Berger ,Roche Pharma Research ,Early Development ,Roche Innovation Centers ,Advancing Translational ,International Foundation ,Ethical Research ,Massachusetts General Hospital ,Massachusetts Medical School ,Massachusetts Institute ,National Academy ,